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of Hom otypic Cell A dhesions
FRANÇOISE ROUSSET,1 MARC BILLAUD,2* DOMINIQUE BLANCHARD, CARL FIGDOR,*
GILBERT M. LENOIR,* HERGEN SPITS,3 a n d  JAN E. DE VRIES3
From UNICBT, Laboratory fo r  Immunological R esearch , DardlUy, France; * International Agency fo r  Research on Cancer, 
Lyon, France; and *the Division of Immunology, The Netherlands Cancer Institu te, Amsterdam, The Netherlands
LFA-1 and LFA-3 expression is absent or low on 
Burkitt’s lymphoma cell lines and low on the EBV- 
transformed B cell line UD61. Incubation of cells of 
BL2 and of UD61 with various concentrations of 
IL-4 resulted in induction of LFA-1 and LFA-3 
expression in a dose dependent fashion. This effect 
was already observed after 16 h of incubation 
whereas maximal expression was obtained after 72 
h. Induction of LFA-1 and LFA-3 expression seemed 
to be specific for IL-4, because IL-1, IL-2, IL-3, IFN-a, 
IFN-y and a low m.w. B cell growth factor were 
ineffective. LFA-1 and LFA-3 induction by IL-4 was 
blocked specifically by an anti-IL-4 antiserum. In­
duction of LFA-1 expression by IL-4 was further­
more confirmed at the specific LFA-1 0-chain m- 
RNA level. IL-4 was unable to induce LFA-1 expres­
sion on EBV-transformed lymphoblastoid cell lines 
of two LFA-1-deficient patients. BL2 grows as single 
cells, but induction of LFA-1 and LFA-3 expression 
by IL-4 was insufficient to induce homotypic cell 
adhesions and required PMA as a second signal. 
PM A alone did not induce LFA-1 antigen expression 
and was unable to induce adhesions between BL2 
cells in the absence of IL-4 in 22 h assays. Addition 
of PMA to BL2 cells that expressed LFA-1 Ag upon 
incubation with IL-4 resulted in aggregate forma­
tion within 30 min. Adhesions between BL2 cells 
induced by IL-4 in combination with PMA were 
blocked by anti-LFA-1/? or anti-LFA-la-chains mAb. 
In addition, these mAbs dispersed preformed aggre­
gates of BL2 cells. Our results indicate that IL-4 can 
induce the adhesion molecules LFA-1 and LFA-3 on 
B cell lines, but that an additional activation signal 
provided by PMA was required for the induction of 
homotypic cell adhesions.
The LFA-14 family consists of the LFA-1 (CDlla),
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CR3bi (GDIlb), and pl50,95 (CDllc) Ag. These hetero­
dimer ic molecules share a common /3-subunit (CD 18) with 
a Mr of 95 kDa, but LFA-1, CR3bi, and p i50,95 have 
different a-subunits with Mr of 180, 170, and 155 kDa, 
respectively (1 , 2).
Antibodies directed against LFA-1 have been shown to 
block every immune response requiring heterotypic cell 
interactions including adhesion reactions between cyto­
toxic T cells or natural killer cells and target cells (3-6), 
Th cells and APC (6- 8). They also block antibody-de­
pendent killing and mixed leucocyte responses (5, 6, 9). 
Furthermore, it was demonstrated that anti-LFA-1 mAb 
prevent or block conjugate formation between cells (9~ 
1 1 ) and disrupt existing conjugates (12, 13), indicating 
that the LFA-1 family Ag act as adhesion molecules,
T or B lymphocytes, EBV-LCL, and monocytoid cell 
lines can be induced to form aggregates after stimulation 
with Ag, lectins, or phorbol esters. These cell-cell inter­
actions could be blocked by anti-LFA-1 mAb indicating 
that this molecule is also associated with homotypic cell 
interactions (12-15).
One natural ligand for LFA-1 is ICAM-1 (CD54), which 
is expressed on leukocytes, fibroblasts, epithelial cells, 
and endothelial cells. mAb against ICAM-1 inhibit con­
jugate formation between cytotoxic T lymphocytes and 
target cells and block adhesions between T cells and 
fibroblasts or endothelial cells (16-18).
The importance of the LFA-1 family molecules in adhe­
sion-dependent processes is illustrated in patients who 
are deficient for these Ag (19-22). These patients suffer 
from persistent leukocytosis, impaired wound healing, 
and severe recurrent bacterial, viral, and fungal infec­
tions (23).
Recently, it has been described that fresh lymphoma 
cells including BL cells lack expression of LFA-1 Ag and 
it has been suggested that these tumor-cells lacking 
LFA-1 fail to induce an immune response, and in this 
way escape from immunosurveillance (24). Furthermore, 
established BL cell lines have been shown not only to be 
deficient in LFA-1, but also in ICAM-1 and LFA-3 (CD58) 
expression (25). Recently, we demonstrated that human 
rIL-4 induced in a coordinated way the expression of both 
CD23 and class II MHC antigens on BL cell lines (26). 
During these investigations, we noticed that also the 
expression of LFA-1 was modulated by IL-4. In our study, 
we show that IL-4 specifically induces/enhances the 
expression of LFA-1 on BL cell lines and on the EBV-LCL
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UD61. LFA-1 induction was confirmed at the LFA-1 i6- 
chain mRNA level. In addition to LFA-1, also LFA-3 
expression was induced by IL-4. Induction of LFA-1 was 
not sufficient for the formation of adhesions between 
cells that required a second signal provided by PM A. 
Aggregate formation was completely prevented by an 
anti-LFA-1 /?-chain mAb and to a lesser extent by anti- 
LFA-1 «-chain mAb. The anti-LFA-1 £-chain mAb also 
dispersed existing aggregates, confirming the notion that 
adhesions between BL2 cells were mediated by LFA-1 
molecules.
MATERIALS AND METHODS
Lymphokines and reagents. Purified rIL-4 (sp, act. 107 U/ml), 
w as a  k ind  gift of Dr. S. N ag ab h u sh an  (Schering C orporation, Bloom­
field, NJ). One u n it of IL-4 is defined as  the co n cen tra tio n  of IL-4 
resu ltin g  in ha lf m ax im al pro liferation  of PHA-activated T  lym pho­
b las ts  (27). H um an r IL - la  w as ob ta ined  from  Drf X. Z u raw sk i (DNAX 
R esearch  Institu te , Palo Alto, CA). rIL-2 w as purchased  from  A m gen 
Biologicals (A m ersham , Inc., UK). IL-3 w as used In th e  fo rm  of 
su p e rn a ta n ts  of Cos 7 cells tran sfec ted  w ith  the  pcD vector c o n ta in ­
ing th e  cloned h u m a n  IL-3 cDNA. GM-CSF tested  a t  co n ce n tra tio n  
of 10 ng /m l (700 pM)t IFN-7 (107 U/mg) and  IFN-« (107 U /mg) u sed  
a t 2 5 0  U/m l w ere provided by Dr. P. T ro tta  (Schering Corp.)- A 
com m ercial p rep ara tio n  of LMW-BCGF w as obtained fro m  C ellu lar 
P roducts  Inc. (Buffalo, NY) a n d  used a t  20% v/v. PM A w a s  o b ta ined
m a (Chemical, St. Louis, MO). T he FITC-conjugated F (ab ')2 
frag m en ts  of goat an tim o u se  Ig used  in  th e  indirect immunofluores*- 
cence  assays  w as p u rch ased  from  G rub (Vienna, A ustria).
Cells and cultures. T he BL cell lines used in th is  s tu d y  w ere  
es tab lish ed  from  C aucasian , N orth A frican, and  A frican  donors a n d  
described  previously (28, 29), Both EBV+ and EBV” cell lines w ere  
te s ted  for th e ir  LFA-1 a n d  LFA-3 expression  (Table I). T h e  EBV-LCL 
UD61 w as estab lished  from  a  hyper-IgE patient, w hose  leucocytes 
exp ressed  norm al levels of LFA-1, EBV-LCL A a n d  B w ere e s ta b ­
lished  from  p a tien ts  su ffe rin g  from  LAD and  kindly provided by D rs.
F. Mi edem a (Central L aboratory  of th e  Red Cross, Blood T ra n s fu s io n  
Service, A m sterdam , T he N etherlands) and  R. Callard (Institu te  fo r 
Child H ealth, London, U.K.) respectively. LCL of th e  p a tie n ts  A a n d  
B expressed  approxim ately  1% a n d  <0.1%  of the  n o rm al a m o u n ts  o f 
LFA-1. These LAD p a tien ts  h av e  been  described previously  (30 -32 ). 
Cell cu ltu res  w ere carried  out in  cu ltu re  medium co n sis tin g  of RPMI 
1640  supp lem ented  w ith  10% h e a t inactivated  FCS, 2 mM  g lu tam in , 
penicillin  (100 IU/ml), an d  strep tom ycin  (100 /ig/ml), a ll from  Flow  
L aboratories, (Irvine, Scotland). T he cell lines were m ycop lasm a free. 
T est cu ltu res  in th e  p resence  of IL-4 or o ther ly m phok ines  w ere  
ca rried  out as described  previously (26).
Antibodies. T he m Ab B1 directed against CD20 w a s  o b ta in ed  
from  Coulter (Hialeah, FL). T he mAb L243 anti-HLA-DR w as p u r ­
ch ased  from Becton D ick inson  (Monoclonal Antibody C en ter, M oun­
ta in  View, CA). mAb SPV-L3 is directed against HLA-DQ (33), W6/  
32  directed ag a in st a  m onom orphic  de te rm inan t on HLA-A, B, C w as  
ob ta ined  from S era  Lab. (Crawley Down, UK). mAb 25 recognizes 
th e  CD23 Ag(34). m A b IOT16 (Im m unotech, M arseille, F rance), SPV-
L7 a n d  SPV -L12 a re  antl-LFA -1 a-chain  antibodies (7). mAb CLB54 
is  d irec ted  a g a in s t  th e  LFA-1 ß~chain (7, 35). The anti-CR3bi m A b 
OKMI w as  o b ta in ed  fro m  O rtho  (Raritan, NJ). The anti-p  150,95 m A b 
S-HCL3 (36) a n d  anti-LFA~3 m A b TS 2/9  (4) were kindly provided 
by  Dr. R. S c h w a rtin g  (Freie U niversität, Berlin, FRD) and  Dr. S. 
B u rak o ff (D ana F ä rb e r  C an ce r Institu te, Boston, MA) respectively. 
T h e  polyclonal ra b b it  an ti-IL -4  an tise ru m  w as raised in  our la b o ra ­
tory. T h is  a n t is e ru m  b locked  specifically  lL-4-mediated pro lifera tion  
of ac tiva ted  T  or B cells, IL-4-induced IgE-synthesis, a n d  did n o t  
re a c t  w ith  rIL -l-a ,-ß , IL-2, IL-3, IL-5, GM-CSF, and  IFN-7 (37). P reim - 
m u n e  se ru m  from  th e  sa m e  ra b b it  was used as control.
Immunofluorescence. A to ta l  of 5 x 105 cells w as Incubated  w ith  
5 0  fû  of th e  ap p ro p ria te ly  d ilu ted  mAb in  0.2-m l m icrotiter p la te  
w ells (V bo ttom , L inbro , T ite r tek , Flow) for 20 m in a t 4°C. A fter tw o  
w a s h e s  w ith  PBS co n ta in in g  1 % BSA and 2 mM azide, th e  cells w ere  
in c u b a te d  w ith  FITC -labeled F (a b ')2 fragm ents of goat an ti-m o use  Ig 
fo r  2 0  m in  a t  4°C, A fte r  th re e  w ash es  w ith PBS con ta in ing  BSA a n d  
azide th e  cells w ere  an a ly zed  w ith  the flow m icrofluorim etry (FACS 
4 4 0 , B ecton D ick inson , S unnyvale , CA). F luorescence d a ta  w ere  
ex p ressed  a s  p e rc e n ta g e  of fluorescen t cells tested  w ith  the  a p p ro ­
p r ia te  m A b com pared  to n o n re le v a n t mAb of Identical isotypes.
In add ition  f lu o re scen ce  w a s  m easured as m ean fluorescence 
in te n s ity  of th e  positive  f lu o rescen t cells expressed a s  the  m e a n  
c h a n n e l n u m b e r  p lo tted  on  a  logarithm ic scale (26).
mRNA analysis. RNA w as prepared  from 5 x 107 cells by u s in g  
th e  g u an id in e  iso th io cy an a te /ce s iu m  chloride centrifugation m eth o d  
(38). A to ta l of 25  fig of eac h  RNA w as size fractionated  on a  1% 
ag aro se  gel c o n ta in in g  2 .2  M form aldehyde and  transferred  to g e n e  
sc reen  nylon  m e m b ra n e s  for hybridization. LFA-1 /3-chain cDNA 
3 .1 .1  k in d ly  p rov ided  by Dr. T. Springer (D ana-Farber In s titu te , 
B oston, MA) (39) w a s  p rep a red  by  random  m ultiprim e labeling. T h e  
level of LFA-1 /3-chain mRNA expression In each cell line w as co m ­
p a re d  to  th e  m RNA level of th e  house keeping gene g lyceraldehyde 
p h o sp h a te  d eh y d ro g en ase  u s in g  the cDNA probe p RGAPDH.13, 
g en e ro u sly  provided  by  Dr. M. Piechaczyc (Université des S ciences, 
M ontpellier, F rance).
Qualitative determination of aggregate formation. Aggregation 
of BL a n d  LCL cells  w a s  de te rm ined  qualitatively as described p re ­
v iously  (40). T h is  m eth o d  is a  modification of the  m ethod described  
by  R o th le in  a n d  S p rin g e r (13), Briefly, cells were resuspended  in  96- 
w ell m ic ro tite r p la te s  (no. 3 0 7 2  Falcon, Meylan, France) a t c o n c e n ­
tra t io n s  of 1 X 105 cells/w ell. Cells were incubated a t  37°C a n d  5% 
C 0 2 for th e  tim es  in d ica ted  in  th e  presence or absence of IL-4 (200 
U/ml), m A b o r  PMA. A ggregate form ation was counted in coded w ells  
in  a n  in v e rted  m icroscope by tw o investigators. Scores ranged fro m
0 to 5 +  in  w h ich  0 in d ica ted  t h a t  essentially no cells w ere aggregated; 
1+, 24- a n d  3 +  in d ic a te  th a t  <10% , <50%, <80% of th e  cells fo rm  
loose c lu s te rs  respectively ; 4 +  indicated th a t >80% of the  ce lls  
fo rm ed  sm a ll d en se  agg regates  and 5+ indicate >90%  of the  cells 
fo rm ed  large co m p ac t c lu s te rs  (40).
Quantitation of aggregate formation. Aggregates of BL a n d  LCL 
cells  w ere  m e a su re d  q u an tita tiv e ly  as  described previously (40). 
Briefly, ce lls  w ere  re su sp e n d e d  in  96-well m icrotiter p la tes  (no. 3 0 7 2  
Falcon) a t  c o n c e n tra t io n s  of 1 x  10s cells/well. Cells w ere in cu b a ted  
a t  37°C a n d  5% C 0 2 fo r th e  times indicated in th e  p resence  or 
a b se n c e  of IL-4 (200 U/m l), m A b (at concentrations of 1 to 10 Mg/ml) 
or PMA (1 o r 10 ng/m l). T h e  num ber of nonaggregated cells w as  
co u n ted  by u s in g  a  c a lib ra te d  ocular in  an  inverted m icroscope. T h e
£
TABLE I
Major characteris tics  of BL  cell lines  u se d a
Cell Line Origin b EBV LFA-1 a 
(SPV-L7)
% Positive Cells
LFA-10
(CLB54)
LFA-3 
(TS 2/9)
Culture
Morphology*-'
BL2 C — 0 0 0 0
BL18 NA + 58 68 54 +++
BL29 A + 0 0 0 +
BL30 C + 4 4 0 + / -
BL31 C — 96 81 ND +++
BL41 C — 0 0 0 0
BL49 C — 0 0 ND +
BL60 NA + 4 4 0 +
BL70 C — 6 5 0 0
BL72 C + 50 55 45 +++
B L 74 C + 22 20 15 +++
Jijoye A 0 0 25 ++
Daudi A + 24 35 15 +
a Presence of EBV in the genome of the cells was determined by im m unofluorescence with anti-EBV-nuclear Ag antibodies 
(28, 29).
bC, Caucasian; NA, North African; A, African.
c 0, single cells only; + / - ,  few small loose aggregates; +, clum ps of 10 to 20 cells; ++, moderately sized aggregates of 50 
cells and considerable num bers of single cells; +++, large aggregates and few single cells.
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m ean  a n d  total n u m b e r  of nonag g rega ting  cells  w a s  co u n ted  in  a t 
least five random ly chosen  a re a s  w h ich  d iffered  fo r  e a c h  well. C o u n t­
ing w as carried  out in d ep enden tly  by  two in v es tig a to rs . P e rc en t 
aggregation w as determ ined  acco rd ing  to  th e  fo rm ula :
% aggregation -  1
no. of nonaggregated  cells 
to ta l n u m b e r  of cells
x 100%
T he experim ents w ere carried  out in  trip lica te . T h e  SD w a s  less th a n  
10%.
RESULTS
LFA-1 and LFA-3 expression on BL cell lines and  
EBV-LCL. Phenotyping of a series of BL cell lines and 
LCL revealed that most of the BL cell lines tested (10/13) 
showed a low or a lack of expression of LFA-1 Ag (Table 
I), whereas only one LCL (UD61) out of 55 tested had 
reduced LFA-1 expression (Fig. 1).
The low or lack of expression of LFA-1-a as detected 
by the mAb SPV-L7, SPV-L12, and IOT16, and LFA-1-0 
as detected by mAb CLB54, was a stable feature of these 
cell lines. Upon repetitive testing over a prolonged culture 
period (4 mo), consistent levels of LFA-1-a and LFA-1-0 
expression were observed (Table I). There seems to be an 
association between the levels of LFA-1 expression and 
the growth characteristics of the BL cell lines. The BL 
which have no detectable, or minimal LFA-1 expression 
grow as single cells (BL2, BL41, BL70), or in small aggre­
gates (BL29, BL30, BL49, BL60) whereas the BL that 
express LFA-1 (BL18, BL31, BL72, BL74) generally grow 
in large aggregates. Exceptions are Jijoye, which is 
LFA-1 “ but grows in medium sized, rather dense aggre­
gates and Daudi, which has relatively high LFA-1 expres­
sion but grows in small clumps (Table I). In contrast to 
EBV-LCL expressing normal levels of LFA-1 and that 
grow in large dense clumps with hardly any single cells, 
cultures of UD61 contain small loose aggregates and also 
single cells (not shown). Finally, it is worth noting that 
EBV-LCL established from the patients BL2, BL41, BL49, 
BL70, and BL74 expressed normal levels of LFA-1, ex­
cluding that the low LFA-1 expression in these patients 
is a genetic defect. In addition, leucocytes of donor UD61 
expressed normal levels of LFA-1 (not shown).
Effect of IL-4 on LFA-1 fam ily  and LFA-3 Ag expres­
sion on BL2 and UD61. The BL cell line BL2 that failed
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Figure 1. Induction of LFA-1 and LFA-3 expression on BL2 and  UD61 
by IL-4. Flow microfluorimetry profiles of BL2 and UD61 cells incubated 
without or with IL-4 (200 U/ml) for 48 h. A t BL2, LFA-la; B, BL2, LFA- 
1/3; C, BL2, LFA-3; D, UD61, LFA-la; E t UD61, LFA-1# F t UD61, LFA-3 
mAb SPV-L7 (anti-LFA-1«), CLB54 (anti-LFA-1/0) and  TS 2 /9  (anti-LFA- 
3) were used. Conjugate control: (sh ad ed  diagrams). A b sc issa ,  log fluo­
rescence intensity; ordinate, relative cell num ber.
to express detectable levels of LFA-1-a and LFA-1-/3 and 
the EBV-LCL UD61 of which only a proportion of the 
cells were LFA-1 positive, were selected for further stud­
ies. Determination of the expression of the other mem­
bers of the LFA-1 family on BL2 and UD61 revealed that 
CR3bi and p i50*95 were absent on both cell lines (Table 
II). In this respect, BL2 does not differ from EBV-LCL, 
that also have been shown to lack expression of CR3bi 
and p i50,95, but in contrast express high levels of 
LFA-1 (1, 13).
Incubation of BL2 and UD61 for 48 h in the presence 
of 200 U/ml of IL-4 induced a significant expression of 
LFA-1-a and LFA-1-/3 on a proportion of the cells (Fig. 1, 
Table II). In contrast, IL-4 failed to induce the expression 
of CR3bi and p i50,95. (Table II). In addition, IL-4 did not 
affect the expression of class I MHC Ag and the specific 
B cell marker CD20 as judged by both the percentage of 
positive cells (Table II) and mean fluorescence intensity 
(not shown), but enhanced, as was shown previously the 
expression of low affinity receptor (FceRII/CD23) and the 
expression of class II MHC Ag (26). IL-4 which has been 
shown to have growth promoting activity for activated B 
cells (41) did not affect the growth of BL2 or UD61 cells 
because no differences in [3H]TdR incorporation were 
observed in the presence or absence of IL-4 (Table II).
BL2 also failed to express LFA-3, whereas LFA-3 
expression on UD61 was very low (Fig. 1). Culturing of 
BL2 and UD61 in presence of IL-4 resulted in the induc­
tion of LFA-3 expression on a significant proportion of 
both cell lines (Fig, 1).
Dose response and kinetics of IL-4 induced LFA-1 
and LFA-3 expression on BL2 and UD61. Culturing BL2 
at various concentrations of IL-4 for 48 h indicated that 
5 U/ml of IL-4 already induced a significant expression 
of LFA-1, that increased in a dose-dependent fashion. 
Maximal expression was obtained at IL-4 concentrations 
between 200-1000 U/ml (Fig. 2). Even at saturating IL-4 
concentration, only a proportion of the cells (37 ± 6% for 
BL2) could be induced to express detectable levels of 
LFA-1. Kinetic studies indicated that IL-4 added at satu­
rating concentrations of 200 U/ml induced significant 
LFA-1 expression on both BL2 and UD61 after 12 to 24 
h (Fig. 3), whereas maximal LFA-1 expression was ob­
tained after 72 h of incubation. Prolonged incubation 
with IL-4 resulted in a decrease in LFA-1 expression (Fig. 
3) which may be due in part to exhaustion of the medium 
and unfavorable culture conditions, because the elevated 
levels of LFA-1 expression were maintained by splitting 
the cultures in fresh medium and IL-4 (not shown). The 
induction of LFA-1 expression by IL-4 was completely 
inhibited by anti-IL-4 antiserum, whereas control rabbit 
sera were ineffective (Fig. 3). These results indicate that 
the effect is indeed specific for IL-4, IL-1, IL-2, IL-3, IFN- 
a, IFN-y, GM-CSF and LMW-BCGF, tested at various con­
centrations, were ineffective in inducing LFA-1 on UD61 
and BL2 cells (Table III).
Induction of LFA-3 followed similar kinetics as shown 
for LFA-1. Also the IL-4 induced LFA-3 expression was 
inhibited by the anti-IL-4 antiserum at a dilution of 1/ 
250, whereas the control preimmune rabbit-serum was 
ineffective (Fig. 4). These results indicate that IL-4 in­
duces the expression of LFA-1 and LFA-3 in a coordi­
nated way.
IL-4 induces transcription of LFA-1 fi-chain-speclflc 
mRNA. The notion that IL-4 induces LFA-1 expression
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TABLE II
induction o f  LFA-1 Ag  on BL2 a n d  UD61 by  IL~4a
Cell Line LymphokineAdded
[3H)TdR Inc. 
(cpm x 10_3±SD)
% Positive Celts (Mean ± SD)
LFA-1 or LFA-1 /3 CR3bl pi 50,95 CD23 HLA-A.B.C CD 20
BL2 0 92 ±  1 1 +  1 0 ± 0 0 ± 0 0 ±  0 0 ± 0 96 ± 2 93  ± 3
IL-4 94 ± 2 31 ±  8 30  ± 11 3 ± 1 0 ± 0 47  ± 5 95 ± 4 96  ± 5
UD61 0 83 ±  1 17 +  7 14 ± 3 0 ± 0 0 ±  0 25  ± 7 95 ± 3 79 ± 7
IL-4 86 ±  4 50 +  7 51 ± 6 1 ± 1 0  ± 0 63 ± 9 95 ± 3 82 + 9
QBL2 and UD61 cells were incubated with 200 U/ml IL-4 for 48 h  and analyzed w ith the FACS. BL2 (mean ± SD of seven experiments); UD61 
(mean ± SD of five experiments). LFA-la, LFA-1/3, CR3bi, p i 50,95, CD23, HLA-A,B,C and CD20 were determined by using mAb SPV-L7, CLB54, 
OKM-1, S-HCL3, 25, W 6/32, and Leu 16, respectively. Proliferation as  measured by [aHJTdR incorporation is expressed as mean cpm X 10-3 ± SD of 
two different experiments.
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Figure 2, Dose response of IL-4-induced LFA-1 expression on BL2 
cells. BL2 cells were incubated for 72 h with different concentrations of 
IL-4. Mean ± SD of three experiments.
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Figure 3. Kinetics of IL-4-induced LFA-1 expression on BL2 and UD61 
cells and it’s inhibition by anti-IL-4 antiserum. IL-4 w as added at a 
concentration of 200 U/ml. □, BL2 + IL-4; O, BL2 + IL-4 4- preimmune 
rabbit serum (1/250); A, BL2 + IL-4 + anti-IL-4 an tiserum  (1/250). ■, 
UD61 + IL-4. Mean ± SD of four experiments. lL-4-induced LFA-1 expres­
sion was also not inhibited by a rabbit anti-hum an ery throcyteantiserum  
(1/250, not shown).
was supported by the finding that IL-4 induced the 
expression of LFA-1 /3-chain specific mRNA. BL2 cul­
tured in the presence of IL-4 at concentrations of of 100 
and 300 U/ml, respectively, for 72 h were found to con­
tain only 14 and 20% LFA-1 positive cells, respectively, 
in this experiment, whereas IL-2 added at a concentration 
of 20 IU/ml or IL-3 were ineffective. Analysis of LFA-1 /3~ 
chain-specific mRNA revealed that although in this ex­
periment a low degree of LFA-1 expression on the mem­
branes was observed, LFA-1 /3-chain mRNA transcription 
was induced in a dose-dependent fashion (Fig. 5). LFA-1
TABLE III 
LFA-J is specifically induced by IL-4a
Lymphokines Added
% LFA-1 Positive Cells (Mean ± SD)
BL2 UD61
0 0.7 ± 0 .6 14.5 ± 2.1
IL-1 a 1 .0  ±  0 .0 12 .Ô ± 1.4
IL-2 3.0 ± 1.0 16.9 ± 1.5
IL-3 0.4 ± 0,6 11.7 ± 0 .4
IL-4 28.6 ± 1.5 48.3 + 3.8
IFN-a 1.0 ± 1 .7 13.8 ±  1.7
IFN-7 0.7 ±1.1 17.2 + 2.5
GM-CSF 3.0 ± 2 ,0 14.3 ± 1.0
LMW-BCGF 3.0 ± 1.7 13.0 ± 2 .8
a BL2 (three experiments) a n d  UD61 (two experiments) were cultured 
for 48 h in the presence of different lymphokines. IL-3 w as tested as 
su p e rn a tan t of Cos-7 cells transfected with the gene encoding human IL- 
3 (1% v/v). IL-1«, IL-2, IL-4, IFN-a, IFN-7 were used at concentrations of 
10, 20, 200, 250, an d  100 U/ml, respectively. GM-CSF was used at 10 
ng/m l an d  LMW-BCGF a t 20% v/v. These lymphokine concentrations 
were found to give optimal effects in stimulation of murine thymocytes 
in the presence of PH A (IL-1«), T cell proliferation (IL-2, IL-4), B cell 
proliferation (LMW-BCGF), bone marrow colony formation (IL-3, GM- 
CSF), and  induction of class II MHC Ag (IFN~a, IFN-7).
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Figure  4. K inetics of IL-4-induced LFA-3 expression on BL2 and UD61 
cells and  it’s  inhibition by anti-IL-4 antiserum. IL-4 w as added a t a 
concentration of 200 U/ml. □ , BL2 4- IL-4; O, BL2 -I- IL-4 + preimmune 
rabbit serum  (1/250); A, BL2 + IL-4 + anti-IL-4 antiserum  (1/250); ■, 
UD61, *f IL-4. M ean ± SD of two experiments. IL-4-induced LFA-3 expres­
sion was also not affected by a  rabbit antihum an erythrocyte antiserum  
(1/250, not shown),
/3-specific mRNA could not be detected when the BL2 
cells cultured in the absence of IL-4, in the presence of 
IL-2, or IL-3 transfection supernatant. IL-4 did not affect 
the constitutive expression of mRNA specific for GAPDH. 
These results indicate that the induction of LFA-1 mem­
brane expression could be confirmed at the specific 
mRNA level.
Effects of IL-4 and anti-LFA-1 mAb on aggregate 
formation . LFA-1 Ag have been shown to act as adhesion 
molecules in heterotypic and homotypic cell interactions, 
including PM A induced formation of homotypic aggre­
gates of EBV-LCL (12, 13). Therefore, we investigated 
aggreSate formation of BL2 cells in the presence of IL-4 
and PMA. BL2 grows as single cells (Fig. 6A). In Figure 
6B, it is shown that although IL-4 induced detectable
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Figure 5. IL-4 induces specific LFA-1 /3~chain mRNA expression in 
BL2. LFA-1 jfr-chain mRNA induction in BL2 after  incubation w ith me­
dium only [lane 2)\ IL-2: 20 IU/ml (lane 3); IL-3, 1% transfection  super­
n a tan t (lane  4), IL-4 100 U/ml (lane 5), IL-4 300 U/ml (lane 6) for 72 h. 
HSB2 (T leukemia cell line) w as used as control (lane 1), Expression of 
GAPDH mRNA was not affected by IL-4. Percentage of LFA-1+ BL2 cells 
after Incubation with medium 0%\ IL-2 1%; IL-4 {100 U/ml) 13%; IL-4 
(300 U/ml) 20%.
levels of LFA-1 expression on 22% of the BL2 cells after 
16 h of incubation, it did not affect the growth charac­
teristics of BL2. Also culturing of BL2 cells in the pres­
ence of PM A ( 1 ng/ml) did not result in detectable levels 
of LFA-1 a/p expression or aggregate formation (Fig. 6C). 
However, BL2 cells cultured in the presence of both IL-4 
and PMA for 16 h formed aggregates (Fig. 6D). No differ­
ences in aggregate formation were observed when PMA 
was added at 1 or 10 ng/ml (not shown). Addition of PMA 
(1 ng/ml) to BL2 cells that had been cultured in the 
presence of IL-4 for 18 h resulted in aggregate formation 
within 2 h (Fig. 6E).
The aggregate formation is mediated by LFA-1, because 
adhesions induced by combinations of IL-4 and PMA did 
not occur in the presence of anti-LFA-1 /?-chain mAb 
CLB54 (Fig. 6F). Anti-LFA-1 «-chain mAb were less ef­
fective. Moderate or slight reductions in aggregate for­
mation were observed in the presence of the anti-LFA-1 
«-chain mAb IOT 16 and SPV-L7, respectively, whereas 
the anti-LFA-1 «-chain mAb SPV-L12 had no effect (not 
shown). Also, the anti-class I MHC mAb W6/32 (Fig. 6G), 
the anti-HLA-DR mAb L243, the anti-HLA-DQ mAb SPV- 
L3, or the anti-CD23 mAb 25 did not affect aggregate 
formation, despite the fact that IL-4 upregulates the 
expression of class II MHC and CD23 expression (26) (not 
shown). The notion that LFA-1 is associated with aggre­
gate formation was furthermore supported by the finding 
that aggregates of BL2 cells formed by incubation with 
combinations of IL-4 and PMA, or after the sequential 
addition of IL-4 and PMA were dispersed 4 h after the 
addition of mAb CLB54 (Fig. 6H, Table IV). The anti- 
LFA-1 fi mAb IOT 16, SPV-L7, and SPV-L12 induced only 
a weak or a nonsignificant dispersion of existing aggre­
gates 4 h after addition, whereas anti-class I MHC (W6/  
32) or anti-class II MHC mAb L243 (HLA-DR) and SPV- 
L3 (HLA-DQ) were ineffective (Table IV). Taken together, 
these data indicate that LFA-1 Ag are involved in adhe­
sions between BL2 cells. However, induction of LFA-1 
expression by IL-4 is insufficient for aggregate formation 
and that a second activation signal delivered via PMA is 
required.
Kinetics of PMA-induced aggregate formation and its
inhibition by anti-LFA-1 mAh. To determine the kinetics 
of aggregate formation induced by PMA more precisely, 
BL2 cells that had been cultured with IL-4 for 16 h were 
subsequently incubated with PMA (1 ng/ml) for various 
time periods. In Figure 7A, it is shown that significant 
aggregate formation was already observed after 30 min 
of incubation, indicating that conversion of LFA-1 to its 
activated state occurred rather rapidly. Maximal levels of 
aggregate formation were obtained 4 h after PMA was 
added. Aggregate formation induced by PMA was strongly 
blocked in the presence of the anti-LFA-1 /3-chain mAb 
CLB54, whereas the anti-LFA-1 «-chain mAb IO 16 or 
SPV-L7 had moderate or weak blocking activity (Fig. 7A). 
The control mAb W6/32 and L243, which are directed 
against class I and class II MHC Ag respectively, did not 
affect the PMA induced aggregate formation. Interest­
ingly, BL2 cells incubated for 16 h with PMA and subse­
quently incubated with IL-4 for various time periods 
started to form low numbers of aggregates after 6 h of 
incubation with IL-4 (Fig. 7B), whereas continuous in­
cubation with PMA for 22 h failed to induce aggregate 
formation,. This aggregate formation was inhibited by 
the anti-LFA-1 $ mAb CLB54.
IL-4 is unable to induce LFA-1 expression on EBV- 
LCLs of LAD patien ts . To determine whether IL-4 could 
induce the expression of LFA-1 in LAD patients, EBV- 
LCL from two LAD patients were incubated with IL-4. 
The EBV-LCL line of patient A expressed strongly re­
duced levels of LFA-1 Ag (1%) when compared to normal 
EBV-LCL, whereas LFA-1 was could not be detected on 
the EBV-LCL of patient B (Table V). Incubation of the cell 
lines with IL-4 at a wide range of concentrations (10 to 
2000 U/ml) for up to 72 h did not enhance or induce LFA-
1 expression. The results with 500 U/ml of IL-4 are 
shown in Table V. In addition, culturing of both EBV- 
LCL in the continuous presence of IL-4 (500 U/ml) for 3 
wk (by changing the medium and by adding 500 U/ml of 
IL-4 twice per week) did not induce or enhance the expres­
sion of surface LFA-1 (not shown). In contrast, a small 
increase in both the percentage and MFI of CD23+ cells 
was obtained (Table V). It is of importance to note that 
these two LCL of the LAD patients predominantly grow 
as single cells with some small loose clumps of maximally 
10 cells. LCL of the LAD patients cultured in the presence 
of IL-4 (500 U/ml) in combination with PMA (10 ng/ml) 
failed to form aggregates, confirming the fact that aggre­
gate formation cannot be induced in the absence of the 
LFA-1 expression (not shown).
DISCUSSION
The majority of the BL cell lines tested in this study 
has a reduced or a lack of expression of LFA-1 family Ag. 
In contrast by screening a large series (n = 55) of EBV- 
LCL, we detected only one LCL (UD61) that consistently 
displayed a reduced expression of LFA-1. Only a propor­
tion of the UD61 cells (maximal 15%) had detectable 
levels of LFA-1 expression whereas all the other EBV- 
LCL tested had high levels of LFA-1 expression on vir­
tually all cells.
There seems to be a correlation between LFA-1 expres­
sion and growth characteristics of the BL cell lines. With 
the exception of Jijoye which is LFA-1 negative, but 
grows in aggregates, the majority of the BL cell lines that 
lack or express very low levels of LFA-1 grow as single 
cells and small loose aggregates. In contrast, BL cells that
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Figured. Growth characteristics of BL2 cells. A f medium; B, IL-4 for 16 h; C, PMA for 16 h; D, IL-4 + PMA for 16 h; E , IL-4 for 16 h, followed by 
PMA for 2 h; F, IL-4 + PMA + mAb CLB54 (1 Mg/ml) for 16 h; G, IL-4 + PMA ± mAb W 6/32 (1/200) for 16 h; H, IL-4 for 16 h. followed by PMA for 2 
h, followed by mAb CLB54 for 4 h. IL-4 was added a t concentrations of 200 U/ml. PMA a t 1 ng/m l.
express considerable levels of LFA-1 grow generally in 
intermediate to large aggregates.
Interestingly, culturing of BL2 and UD61 in the pres­
ence of IL-4 resulted in induction or enhancement of 
LFA-1 expression on BL2 and UD61 cells, respectively. 
Induction of LFA-1 expression seems to be specific for 
IL-4, because IL-1-a, IL-2, IL-3, GM-CSF, LMW-BCGF, 
IFN-a and IFN-7 were ineffective. In addition, the LFA-1- 
inducing effect of IL-4 was completely inhibited by the 
anti-IL-4 antiserum. Although IL-4 has growth promoting 
activity on activated B cells (41), it could be excluded that 
induced/enhanced expression of LFA-1 reflects the selec­
tive outgrowth of a minor subpopulation of LFA-1 cells, 
because no differences in proliferation were observed 
between BL and LCL cultured in the presence or absence 
of IL-4 (Table II). The notion that IL-4 induced de novo
LFA-1 expression was confirmed at the specific mRNA 
level. IL-4 added at concentrations of 100 and 300 U/ml 
induced transcription of LF A-1 ^ -specific mRNA in a 
dose-dependent fashion, whereas the constitutive mRNA 
transcription of the house keeping gene GAPDH was not 
affected. In the absence of IL-4, no constitutive LFA-1 
ft-chain-specific mRNA expression could be detected.
In addition to the induction of LFA-1 expression, IL-4 
was also found to induce the expression of LFA-3 which 
recently has been shown to represent one of the natural 
ligands of CD2 (42-45). Inasmuch as limited quantities 
of anti-LFA-3 antibodies were available, induction of 
LFA-3 by IL-4 was not studied in detail, but the data 
obtained thusfar indicate that it followed similar kinetics 
as that shown for LFA-1 suggesting that the expression 
of LFA-1 and LFA-3 are induced in a coordinated fashion.
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TABLE IV
D ispersion o f preformed aggregates of BL2 cells ind u ced  by IL-4 in
presence of' PMAa
Aggregates Incubated with: Aggregation Score
Medium 3+
CLB54 (LFA-10) <14-
SPV-L7 (LFA-1 a) 2+
SPV-L12 (LFA-1 a) 3+
IOT 16 (LFA-la) 2+
25 (CD23) 3+
W 6/32 (HLA-A.B.C) 3+
L243 (HLA-DR) 3+
SPV-L3 (HLA-DQ) 3+
a BL2 cells were cultured with IL-4 (200 U/ml) and  PM A (1 ng/ml) for
40 h. mAb CLB54, SPV-L7, SPV-L12, IOT-16, SPV-L3, and  L243 were 
added at a concentration of 1 Mg/m 1. W6/32 w as added a t a  dilution of 1/ 
200. Aggregates were scored after 4 h of incubation at 37°C and 5% C02 
in the presence of the various mAb. The mAb CLB54, SPV-L7, SPV-L12, 
IOT-16, SPV-L3, and L243 tested at 5 fig/m 1 and  W 6/32 diluted 1/50 gave 
similar blocking results (not shown).
Taken together these data indicate that IL-4 in addition 
to its capacity to induce CD23 (26, 46) and class II MHC 
Ag (26) on normal B cells and BL cell lines, also induces 
the induction of LFA-1 and LFA-3 Ag. IL-4 did not induce 
the expression of detectable levels of the other members 
of the LFA-1 family, despite the fact that CR3bi and 
p i50,95 share the same /9-chain. The mechanisms un­
derlying the preferential induction of LFA-1 expression 
by IL-4 remain to be determined, but it may be possible 
that it is related to the cell type studied, because recently 
we demonstrated that induced the expression of CR3bi 
and pi 50,95 on human monocytes, whereas LFA-1 
expression remained unaltered (47). Also Springer and 
Anderson (48) have shown that individual members of 
the LFA-1 family can be independently modulated upon 
cell activation.
BL2 is growing in single cells and does not form aggre­
gates and therefore can be classified to belong to the 
group I BL, which according to their cell surface markers 
are identical to biopsy obtained BL cells (49). Clayberger 
et aL (24) reported that a proportion of lymphomas, in­
cluding the majority of biopsy obtained BL, failed to ex­
press LFA-1, indicating that the lack or reduced LFA-1 
expression on BL cell lines studied is not the result of in 
vitro culture conditions. These LFA-1-deficient BL cells 
were very poor stimulators of both autologous and allo­
geneic T cell responses, and an initial survey indicated 
that LFA-1 expression on these lymphoma cells corre­
lated with relapses (24). Therefore these authors sug­
gested that the tumor cells lacking LFA-1 cannot initiate
efficient immune responses in vivo, which might contrib­
ute to the escape of these tumors from immunosurveil- 
lance. However, we demonstrate here that BL2 cells also 
lacked expression of LFA-3, which is a natural ligand for 
CD2 that is involved in the alternative T cell activation 
pathway (50-52). In addition, recently it has been dem­
onstrated that BL (including BL2) have defective expres­
sion of ICAM-1 (25), which is one of the natural ligands 
of LFA-1 (16-18). We and others (11, 51) have demon­
strated that destruction of target cells by allospecific CTL 
clones is preceded by Ag nonspecific adhesions that are 
mediated via two different adhesion pathways in which 
effector cell LFA-1 and target cell ICAM-1, and effector 
cell CD2 and target cell LFA-3 are involved (51-52). 
Therefore, the general absence or very low expression of 
adhesion molecules may account for the failure of BL to 
form adhesions with T cells and subsequent induction of 
T cell responsiveness. This notion is supported by our 
findings that conjugate formation between CD4+ T cell 
clones and BL2 cells is reduced when compared to that 
between these T cell clones and the EBV-LCL of patient 
BL2 which expressed normal levels of LFA-1 and LFA-3 
respectively (D. Blanchard and H. Spits, unpublished 
data). Furthermore, recent murine studies have demon­
strated that IL-4 indeed augmented adhesions between 
Ag-specific T and B cells after B cells had been incubated 
with IL-4 (53), but the increased conjugate formation was 
attributed to enhanced class II MHC expression. Although 
IL-4 also enhances class II MHC expression on BL2 cells 
(26) anticlass II MHC antibodies failed to prevent the 
formation of homotypic aggregates. In contrast, prelimi­
nary data obtained with human B cells indicated that 
also enhances LFA-1 expression on normal purified ton­
sillar B cells as judged by an increase of the mean fluo­
rescence intensity. In addition, the increased expression 
of LFA-1 observed upon activation of the B cells was 
further enhanced in the presence of IL-4 (F. Rousset, 
unpublished).
Despite the fact that IL-4 induces LFA-1 expression on 
BL2 cells, this did not result in adhesion between BL2 
cells and aggregate formation. Homotypic cell/cell inter­
actions were only induced when IL-4 was added simul­
taneously with PMA. Also addition of PMA to BL2 cells 
cultured in IL-4 for 16 h resulted in induction of aggregate 
formation within 30 min, without enhancing LFA-1 
expression. PMA added alone for 18 h was ineffective in 
inducing LFA-1 expression or aggregate formation. Fur-
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Figure 7. Kinetics of aggregate formation (mean ±  SD of two experiments). A, BL2 cells were preincubated with IL-4 (200 U/ml) for 16 h; PMA or 
mAb were added a t time 0. □, PMA (1 ng/ml); O, PMA + W 6/32 (1/200); A, PMA + SPV-L7 (1 Mg/ml); A, PMA + IOT 16 {1 /¿g/ml); ■, 
PMA + CLB54 (1 /ig/ml); O, medium. B, BL2 were preincubated w ith  PMA (1 ng/ml) for 16 h. IL-4 was added at time 0. A, PMA (1 ng/ml); □, PMA (-16 
h) + IL-4; ■, PMA + IL-4 + CLB54 (1 ng/ml).
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TABLE V
E ffec ts  of IL-4 on LFA-1 a, fi expression on LCL Jrom LAD p a tie n tsa
Cell Line 
Incubated with
% Positive Cells
LFA-1 a LFA-1 ß CD23 Class I-MHC
Patient A none 1 ± 1 2 ±  1 67 ± 5 95 ±  1
IL-4 3 ± 2 3 ±  1 83 ±  4 94 ± 2
Patient B none 0 ± 0 0 ± 0 81 ± 2 98 ± 1
IL-4 0 ±  1 2 ± 1 91 ± 4 95  ± 2
a Cells of LCL of LAD patients A and B were incubated w ith  IL-4 (500 
U/ml) for 72 h. LFA-la, LFA-1/3, CD23, and class I MHC Ag were deter­
mined by using mAb SPV-L7, CLB54, 25, and W6/32, respectively. Mean 
± SD of six experiments.
thermore, aggregate formation induced by IL-4 and PMA 
was blocked effectively by the anti-LFA-l /3-chain mAb 
CLB54 and, to a lesser extent by the anti-LFA-l «-chain 
mAb SPV-L7, SPV-L12 and IOT 16. The anti-LFA-1 
/3-chain mAb CLB 54 dispersed aggregates that were al­
ready formed more efficiently than anti-LFA-1 a-chain 
mAb, which had only weak effects. These results indicate 
that the LFA-1 molecules were involved in aggregate 
formation.
The LCL of the LAD patients which could not be in­
duced to express LFA-1 Ag also did not form aggregate in 
the presence of IL-4 or in the presence of IL-4 in combi­
nation with PMA, confirming the notion that aggregate 
formation can not be induced in the absence of LFA-1 
expression. The defective LFA-1 expression in LAD pa­
tients varies and can reflect defects at the DNA or RNA 
level or can be attributed to posttranslational protein 
modifications (22, 38, 54-56). The actual defects in the 
patients studied here are not known, but our data indi­
cate that IL-4 added at a large concentration range and 
for prolonged periods cannot restore LFA-1 expression. 
These data are in line with results that were reported by 
Rothlein and Springer ( 13) who showed that PMA induced 
a strong aggregation of normal LCL, but was unable to 
induce aggregate formation by LCL of LAD patients. PMA 
did not induce LFA-1 expression on BL2 cells, addition 
of IL-4 to BL2 cells that had been incubated in PMA for 
16 h resulted in a low degree of LFA-1 expression and 
aggregate formation after 6 h, whereas continuous incu­
bation in PMA for 22 h did not result in aggregate for­
mation. These results confirm the notion that both IL-4 
and PMA are required for aggregate formation and indi­
cate that LFA-1 is more rapidly induced on PMA-treated 
BL2 cells.
Collectively, our data indicate that IL-4 induces LFA-1 
expression, but that a second signal provided by PMA is 
required to convert the LFA-1 molecule from an inactive 
to an active configuration, thereby allowing binding of 
LFA-1 to ICAM-1. Inasmuch as PMA activates PKC (57), 
it may be possible that addition of PMA results in an 
intracellular signal that activates PKC, resulting in sub­
sequent phosphorylation of the LFA-1 /?~chain. Molecular 
cloning of LFA-1 /?-chain revealed that it contained var­
ious possible phosphorylation sites including four serine 
residues (38). The notion that LFA-1 can become phos- 
phorylated via PKC is supported by the finding that only 
the serine residues of the /?-chain were found to be phos- 
phorylated (58).
Our data indicate that LFA-1 is not an adhesion initi­
ating molecule, but requires a structural modification or 
activation before it contributes to adhesion strengthen­
ing. Such an adhesion strengthening role of LFA-1 has 
also been proposed by others (13, 59). The natural signal
that would induce the activated state remains to be de­
termined, but LFA-1 activation may be induced via other, 
LFA-1-independent adhesion pathways, such as those 
between CTL and target cells mediated via CD2 and LFA- 
3 or by the weak LFA-1-independent cell-cell interactions 
that precede LFA-1-dependent adhesions (60-62). Fi­
nally, it remains to be determined whether the low levels 
of ICAM-1 in type I BL cell lines like BL2 (25) are sufficient 
to allow aggregate formation or whether IL-4 also simul­
taneously up-regulates ICAM-1 expression.
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